查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840693

末期肾病市场按治疗方式、存取类型和最终用户划分 - 全球预测 2025-2032 年

End Stage Renal Disease Market by Treatment Modality, Access Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，末期肾臟病市场规模将达到 1,649.7 亿美元，复合年增长率为 15.22%。

主要市场统计数据
基准年 2024 530.9亿美元
预计年份：2025年 610.4亿美元
预测年份：2032年 1649.7亿美元
复合年增长率 (%) 15.22%

全面介绍正在再形成终末期肾病护理服务和相关人员优先事项的不断变化的临床和运营动态。

末期肾病 (ESRD) 涉及临床、营运和经济等诸多复杂挑战，影响整个医疗保健系统、医疗服务网络和患者群体。病患族群老化，且常伴随多种併发症，使得治疗方法选择更加复杂，也推动了对整合式医疗服务路径的需求。同时，透析方法、血管通路、移植通讯协定和数位疗法等方面的技术进步正在重塑临床决策和医疗服务模式。这些变化既为临床医生、采购团队、製造商和支付方带来了机会，也带来了压力，他们必须在临床疗效、可负担性和可及性之间取得平衡。

近年来，患者的偏好已转向以最大限度提高生活品质和最大限度减少干扰为导向的护理，这促使人们对中心护理和居家护理进行策略性重新评估。监管挑战和报销框架也开始反映这一转变，激励那些能够展现临床疗效和成本控制的模式和服务设计。同时，劳动力短缺和供应链脆弱性迫使医疗服务提供者和供应商奖励其在采购、物流和培训方面的投入。因此，相关人员越来越重视那些能够提供临床可靠性、灵活的交付模式和全面支援服务的解决方案。

本执行摘要概述了影响末期肾病 (ESRD) 诊疗的关键趋势和策略意义。它重点阐述了临床创新、营运韧性和相关人员协作之间的交集，并组装了领导者必须解答的问题，以维持为日益增长且病情复杂的患者群体提供高品质的诊疗服务。本概要着重于以病人为中心的诊疗方法和系统层面的效率提升，为领导者在应对短期挑战的同时，确保其机构在临床和经济效益方面持续保持领先地位提供了切实可行的指导。

识别末期肾臟病护理中推动模式转变、供应链韧性、劳动力重组和以患者为中心的创新的关键系统转型

除了临床疗效的逐步提升，末期肾病（ESRD）领域正在经历一系列变革性转变，这些转变正在重新定义医疗模式和相关人员关係。技术创新加速了居家治疗模式和远端监测平台的普及，减轻了患者的出行负担，并透过持续的数据流实现了早期疗育。同时，政策转向以以金额为准为导向，使得医疗协调、依从性支援和疗效评估在医疗服务提供者合约和报销谈判中发挥越来越重要的作用。这些因素共同推动着更分散化、以病人为中心的医疗模式的形成。

劳动力压力和临床医生角色的演变也在重塑营运模式。肾臟病团队正透过跨学科诊疗路径调整运营，并扩大护理师主导和远端医疗主导，以维持医疗服务的可及性和品质。供应链韧性已成为一项核心策略重点，推动对本地製造能力、多元化供应商网路以及能够抵御地缘政治和物流衝击的库存管理系统的投资。此外，血管通路技术和移植管理的技术创新正在改变患者的长期治疗轨迹，影响透析中心和移植计画的容量规划。

最后，老年人及其看护者数位素养的提升正在迅速提高患者的参与度和共同决策能力。将易用性、教育和心理社会支持融入产品和服务设计的医疗机构和供应商，正在获得更高的患者共用和更好的治疗效果。总而言之，这些转变代表着一个正在向整合式照护路径、技术赋能的居家养老选择以及风险共担机制迈进的生态系统，这些机制奖励以患者为中心的指标取得显着改善。

分析2025年关税如何重塑末期肾病（ESRD）照护筹资策略、生产布局、供应链风险管理和临床资本规划。

美国将于2025年实施关税，这将改变医疗设备、耗材和药品供应链的成本结构和筹资策略，对终末期肾病（ESRD）相关人员产生重大的下游影响。进口关税影响了透析设备、耗材和血管通路装置的采购决策，迫使製造商和医疗服务提供者重新评估其区域製造地和长期供应商关係。为此，许多公司加快了近岸外包的步伐，并扩大了与国内製造外包的伙伴关係，以降低跨境价格波动和前置作业时间风险。

随着总成本估算变得更加难以预测，采购团队面临着更为复杂的挑战，导致其关注点从单位成本转向更广泛的采购指标，例如交付可靠性、品质保证和供应商多元化。这种转变也影响了他们与设备製造商和分销商的谈判能力，后者越来越多地将服务和维护合约捆绑在一起，以确保稳定的收入来源，同时为客户提供可预测的生命週期支援。同时，由于需要评估不断上涨的设备和耗材成本的财务影响，临床医生和医院管理人员也受到了采购週期变化和资本投资延迟等间接影响。

在技​​术创新方面，研发蓝图进行了调整，优先发展本地组装的模组化平台，以减轻关税的影响并支持灵活的生产规模化。产业协会和医疗系统领导者积极倡导对关键医疗用品实施关税豁免和定向减免，以确保弱势患者群体能够获得价格合理的医疗服务，相关部门对该计画的参与度也随之提高。整体而言，2025年关税的累积影响促使策略规划重新聚焦于供应链的灵活性、采购的精细化以及计画倡导，以保障终末期肾病患者的持续治疗。

透过细分市场分析，主导了解治疗方式、血管通路和护理环境之间的相互依存关係如何决定终末期肾病服务的临床路径、营运需求和投资重点。

透过细分获得的洞见揭示了治疗方法选择、血管通路和护理环境如何相互作用，从而塑造临床路径和营运需求。治疗方式包括血液透析机、腹膜透析和肾臟移植，其中血液透析机可细分为居家透析和中心透析模式，而腹膜透析则分为持续性非卧床腹膜透析和持续性循环腹膜透析。这些细分会影响采购、培训和依从性支援的优先事项，因为每种治疗方式及其子模式对设备、病患教育、监测基础设施和长期临床追踪的需求各不相同。

血管存取类型分类有助于明确动静脉瘻管、中央静脉导管和人工血管等不同选择在临床和操作层面的权衡取舍。血管通路的选择直接影响併发症发生率、住院风险和维护通讯协定的强度，进而影响人员配置模式和辅助服务需求。因此，医疗机构必须使其血管通路方案与治疗策略相匹配，以优化患者预后并减少不必要的医疗资源消耗。

这项调查的最终用户群体——透析中心、居家照护机构和医院——揭示了各自不同的营运模式和服务期望。透析中心强调吞吐量、标准化通讯协定和打包服务，而居家照护则优先考虑患者培训、远端监测和物流供应。医院需要整合的急性护理路径和快速併发症处理机制。了解这些群体之间的互动方式，有助于管理者设计针对特定治疗模式的服务包，协调临床医生培训，并优先考虑能够提升临床疗效和患者体验的投资。

对美洲、欧洲、中东和非洲以及亚太地区的动态如何影响终末期肾病（ESRD）护理模式的采用、基础设施投资和政策进行区域分析。

区域动态对末期肾病（ESRD）的医疗服务选择、投资重点和监管方式有显着影响。美洲的医疗体系涵盖单一支付方和混合支付方，这影响报销方式、居家治疗方法的普及率以及私人机构参与医疗服务的程度。儘管该地区在医疗设备应用和远端医疗整合方面往往处于领先地位，但农村地区也面临劳动力短缺的困境，这限制了医疗服务的可近性。政策辩论和支付方的倡议影响着国家和地区层面的资本配置和基于价值的医疗奖励。

在欧洲、中东和非洲，法规环境和基础设施能力的差异导致了不同的应用模式。高所得的欧洲市场拥有严格的临床标准和完善的报销机制，支持创新技术的应用和健全的移植项目；而欧洲、中东和非洲的新兴市场则面临基础设施不足、透析能力有限和资金筹措限制等问题，因此需要可扩展且资源成本低的解决方案。跨境采购和区域製造中心在提高供应可靠性和成本效益方面发挥着日益重要的作用。

亚太地区拥有快速成长的需求、多元化的支付方结构以及强大的製造业基础，这为国内生产和出口提供了有力支撑。该地区许多医疗系统正在投资居家医疗模式和数位化平台，以扩大都市区和城郊人口的医疗服务覆盖范围，同时兼顾扩大移植基础设施和人才队伍建设的需求。该地区各相关人员必须使其策略与当地政策驱动因素、基础设施现状和人口趋势相契合，以确保服务的可持续提供和患者公平获得医疗服务。

深入剖析了该公司如何透过结合产品创新、整合服务、供应链敏捷性和卓越的监管能力，引领终末期肾病医疗保健的策略。

活跃于末期肾病 (ESRD) 生态系统中的各公司之间的竞争与合作正在塑造产品设计、服务交付模式和售后支援策略。产业参与者正日益从纯粹以产品为中心的模式转向整合服务包，将设备、耗材、培训、维护和数位化监控相结合。这种转变响应了医疗服务提供者对可预测结果的需求以及支付方对可衡量、以价值为导向的指标的关注。因此，能够提供可靠的临床证据、全面的培训计划和可靠的现场服务能力的公司在合约谈判中拥有明显的优势。

随着企业寻求加速渐进式创新产品的上市速度并共用研发风险，策略伙伴关係、授权协议和联合开发倡议正变得越来越普遍。製造外包和本地组装策略也在不断扩展，以减轻关税的影响并缩短前置作业时间。投资于互通软体和开放资料方法的企业可以参与医疗网路和人口健康倡议。此外，售后服务——从耗材供应物流到预测性维护和远端故障排除——正在成为影响客户维繫和终身价值的关键差异化因素。

最后，那些优先考虑监管合规和卫生经济学证据产生的公司将更容易获得优质采购管道，并与支付者进行更有效的谈判。最具韧性的公司将强大的临床研发管线、可扩展的服务模式和灵活的供应链结合，以满足不同医疗机构中医疗服务提供者和患者不断变化的需求。

为领导者提供行动建议，以扩大居家治疗模式、加强供应链、推进数位整合并影响政策，从而确保末期肾病 (ESRD) 的长期疗效。

行业领导者必须采取果断而协调的措施，将不断变化的证据和营运压力转化为可持续的竞争优势。首先，各机构应优先发展居家治疗模式，并辅以完善的病患教育和远距监测项目，以符合病患偏好并减轻系统层面的负担。此类投资应辅以清晰的临床路径和结果指标，从而实现持续改善。其次，企业和医疗服务提供者必须透过近岸外包、多通路采购和有效的本地伙伴关係来实现供应链多元化，以降低关税波动和物流中断带来的风险。

第三，相关人员可互通的数位平台，整合设备远端检测、电子健康记录和病患报告结果，以支援主动式照护管理和基于价值的合约。第四，劳动力发展至关重要。应投资于可扩展的培训项目，提升护理师、技师和护理协调员的技能，以支援居家护理和远距远端医疗的工作流程。第五，应积极与政策制定者和支付方合作，制定报销框架，奖励在以病人为中心的结果、医疗服务可近性和长期成本效益方面取得显着进步的措施。最后，应采取组合式创新方法，平衡短期营运改善与对移植支援、血管通路创新和微创技术的长期投资。

透过协调一致地实施这些行动，领导者可以改善临床结果，保护利润免受外部衝击，并使他们的组织在护理模式不断发展的过程中保持持续的领先地位。

采用严谨的多方法调查方法方法，结合相关人员参与、文献回顾、用例分析、情境测试和专家咨询检验。

这些研究成果基于一种多方法研究策略，旨在整合临床证据、营运实践和政策制定。一级资讯来源包括与临床医生、供应链经理、医疗系统高管和支付方举行的结构化会议，以了解他们对治疗方式采纳、准入管理和采购挑战的现场观点。二级资讯来源包括同行评审的临床文献、监管文件、临床实践指南和公共文件，以检验临床疗效和监管趋势。这些资讯被纳入定性综合和主题分析，重点关注患者就诊路径、器械生命週期管理和服务模式经济学。

为确保研究的稳健性，调查方法纳入了针对示范性医疗服务体系和供应商的用例，这些体系和供应商已成功实施了家庭透析治疗规模化、整合远端监测和弹性筹资策略。情境分析考虑了各种可能的供应链和政策发展趋势，以对策略选择进行压力测试。在资料完整性方面，研究对采购和监管资料点进行了交叉检验，仔细记录了访谈通讯协定，并根据相关人员的回馈不断调整，以最大限度地减少偏差，确保研究结果在不同医疗环境中的适用性。

这种多层次的方法将深入的定性见解与严谨的文献证据相结合，为寻求改善终末期肾病 (ESRD) 患者治疗效果和运营韧性的临床医生、管理者和商业性相关人员提供可操作的见解。

总结性综述强调了临床创新、营运韧性和协作策略之间的相互作用，以改善末期肾病 (ESRD) 治疗的效果和可及性。

总体而言，末期肾病治疗正处于曲折点，临床创新、政策奖励和营运限制正在交汇融合，重塑服务的提供和资金筹措方式。对居家医疗的日益重视，以及血管通路和监测技术的进步，为改善病患体验和治疗效果提供了实际的机会。然而，这些机会也伴随着持续存在的挑战，包括医护人员短缺、基础设施不足和供应链脆弱性，这些都需要製定周密的应对策略。

积极调整采购、临床路径和数位化整合的领导者将更有能力应对外部衝击并实现以金额为准目标。同样重要的是，需要采取协作方式，将临床医生、支付方、製造商和患者权益倡导者聚集在一起，共同设计可在各种环境下推广的实用解决方案。透过专注于模组化、可互通的解决方案，加强区域製造商和供应商网络，并严格衡量以患者为中心的结果，相关人员可以在保持卓越临床水平的同时，提高医疗服务的可及性和韧性。

推动这项工作需要各方共同投入和严格执行。将这些洞见融入策略规划的机构，不仅能改善末期肾病患者的护理，还能建构可持续的商业模式，抵御市场和政策的波动。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将远距远端医疗应用于居家血液透析机可以提高患者依从性并降低住院率
  • 穿戴式人工肾臟的出现，旨在为门诊透析患者改善活动能力和生活品质。
  • 扩大精准医疗生物标记的应用范围，以预测残余肾功能下降并制定个人化治疗方法
  • 为了满足不断增长的需求并降低新兴市场的医疗保健成本，对腹膜透析基础设施的投资正在增加。
  • 将人工智慧演算法整合到透析设备中，用于即时监测和预测性维护警报

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 末期肾病市场：依治疗方式划分

  • 血液透析机
    • 在家里
    • 设施内部
  • 腹膜透析
    • 持续性携带式腹膜透析
    • 连续循环腹膜透析
  • 移植
    • 已故捐赠者
    • 活体捐赠者

9. 依存取类型分類的末期肾病市场

  • 动静脉瘻管
  • 中央静脉导管
  • 合成接枝

第十章 以最终用户分類的末期肾病市场

  • 透析中心
  • 居家照护
  • 医院

第十一章 各地区末期肾病市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 末期肾病市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国末期肾病市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Fresenius Medical Care AG & Co. KGaA
    • DaVita Inc.
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Nipro Corporation
    • NxStage Medical, Inc.
    • US Renal Care, Inc.
    • Satellite Healthcare, Inc.
    • Dialysis Clinic, Inc.
    • Jafron Biomedical Co., Ltd.
Product Code: MRR-DA46DD749C68

The End Stage Renal Disease Market is projected to grow by USD 164.97 billion at a CAGR of 15.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 53.09 billion
Estimated Year [2025] USD 61.04 billion
Forecast Year [2032] USD 164.97 billion
CAGR (%) 15.22%

Comprehensive introduction to the evolving clinical and operational dynamics that are reshaping End Stage Renal Disease care delivery and stakeholder priorities

End Stage Renal Disease (ESRD) poses a complex blend of clinical, operational, and economic challenges that reverberate across healthcare systems, provider networks, and patient communities. Patient populations are aging and increasingly present multiple comorbidities, which complicates treatment selection and intensifies demand for integrated care pathways. Concurrently, technological advances in dialysis modalities, vascular access, transplantation protocols, and digital therapeutics are reshaping clinical decision-making and care delivery models. These changes create both opportunities and pressures for clinicians, procurement teams, manufacturers, and payers who must balance clinical outcomes with affordability and access.

In recent years, patient preferences have shifted toward treatments that maximize quality of life and minimize disruption, prompting a strategic reassessment of in-center care versus home-based therapies. Regulatory agendas and reimbursement frameworks have begun to reflect that shift, incentivizing modalities and service designs that demonstrate clinical effectiveness and cost containment. At the same time, workforce constraints and supply chain fragilities are forcing providers and vendors to rethink sourcing, logistics, and training investments. As a result, stakeholders increasingly prioritize solutions that deliver clinical reliability, flexible delivery models, and integrated support services.

This executive summary synthesizes the essential trends and strategic implications shaping ESRD care. It emphasizes the intersection of clinical innovation, operational resilience, and stakeholder alignment, and it frames the questions leaders must answer to sustain high-quality care for growing, complex patient cohorts. By foregrounding patient-centric approaches and system-level efficiencies, the summary offers a practical orientation for leaders seeking to navigate near-term disruptions while positioning their organizations for sustained clinical and economic performance.

Identification of the major systemic transformations in ESRD care that are driving modality shifts, supply chain resilience, workforce reconfiguration, and patient-centered innovation

The ESRD landscape is undergoing a sequence of transformative shifts that extend beyond incremental clinical improvements to redefine care models and stakeholder relations. Technological innovation has accelerated the adoption of home modalities and remote monitoring platforms, reducing patient travel burden and enabling earlier intervention through continuous data streams. Simultaneously, policy shifts emphasize value-based outcomes, which elevates the role of care coordination, adherence support, and outcome measurement in provider contracting and reimbursement conversations. These forces together are driving a more decentralized, patient-centered model of care.

Workforce pressures and evolving clinician roles are also reshaping operational models. Nephrology teams are reallocating tasks through multidisciplinary care pathways and expanding nurse-led and telehealth-driven services to maintain access and quality. Supply chain resilience has become a core strategic priority, prompting investment in local manufacturing capabilities, diversified supplier networks, and inventory management systems that can withstand geopolitical and logistic shocks. Moreover, innovation in vascular access techniques and transplant management is altering long-term patient trajectories, thereby influencing capacity planning for dialysis centers and transplant programs.

Finally, patient engagement and shared decision-making are advancing rapidly as digital literacy increases among older adults and caregivers. Providers and vendors that embed usability, education, and psychosocial supports into product and service designs achieve higher adherence and better outcomes. Taken together, these shifts indicate an ecosystem moving toward integrated care pathways, technology-enabled home options, and risk-sharing arrangements that reward demonstrable improvements in patient-centric metrics.

Analysis of how 2025 tariff measures have reshaped procurement strategies, manufacturing footprints, supply chain risk management, and clinical capital planning for ESRD care

The implementation of United States tariffs in 2025 has created material downstream effects for ESRD stakeholders by altering cost structures and procurement strategies across the device, consumable, and pharmaceutical supply chains. Import levies have influenced sourcing decisions for dialysis machines, disposables, and access devices, prompting manufacturers and providers to re-evaluate regional manufacturing footprints and long-term supplier relationships. In response, many organizations accelerated nearshoring initiatives and expanded partnerships with domestic contract manufacturers to mitigate exposure to cross-border price volatility and lead-time risks.

Procurement teams faced greater complexity as total landed costs became less predictable, which in turn shifted emphasis from unit price alone to broader procurement metrics such as delivery reliability, quality assurance, and supplier diversification. These shifts also affected negotiation dynamics with original equipment manufacturers and distributors, who increasingly offered bundled service and maintenance contracts to preserve stable revenue streams while providing clients with predictable lifecycle support. In parallel, clinicians and hospital administrators experienced indirect impacts through altered purchasing cycles and delayed capital investments, as organizations assessed the financial implications of higher equipment and consumable costs.

On the innovation front, R&D roadmaps adjusted to prioritize modular, locally assemblable platforms that reduce tariff exposure and support flexible production scaling. Policy engagement intensified as industry groups and health system leaders advocated for tariff exemptions or targeted relief for critical medical supplies to preserve access and affordability for vulnerable patient populations. Overall, the cumulative impact of 2025 tariff measures has been to refocus strategic planning on supply chain agility, procurement sophistication, and policy advocacy to safeguard continuity of care for ESRD patients.

Segment-driven insights into how modality, vascular access, and care setting interdependencies define clinical pathways, operational demands, and investment priorities for ESRD services

Insights derived from segmentation reveal how modality choice, vascular access, and care setting interlock to shape clinical pathways and operational requirements. Treatment Modality considerations encompass Hemodialysis, Peritoneal Dialysis, and Transplant, with Hemodialysis further differentiated between Home and Incenter delivery models, and Peritoneal Dialysis separated into Continuous Ambulatory Peritoneal Dialysis and Continuous Cycling Peritoneal Dialysis; Transplant pathways distinguish patient journeys by Deceased Donor and Living Donor sources. These distinctions matter because each modality and sub-modality drives different needs for capital equipment, patient education, monitoring infrastructure, and long-term clinical follow-up, thereby influencing procurement, training, and adherence support priorities.

Access Type segmentation clarifies clinical and logistical trade-offs across Arteriovenous Fistula, Central Venous Catheter, and Synthetic Graft options. Vascular access choice directly affects complication rates, hospitalization risk, and the intensity of maintenance protocols, which in turn shapes staffing models and ancillary service demand. Providers must therefore align vascular access programs with modality strategies to optimize patient outcomes and reduce avoidable utilization.

End User segmentation, which examines Dialysis Centers, Home Care Settings, and Hospitals, highlights divergent operational models and service expectations. Dialysis centers emphasize throughput, standardized protocols, and bundled service offerings, whereas home care settings prioritize patient training, remote monitoring, and supply delivery logistics. Hospitals require integrated acute care pathways and rapid escalation mechanisms for complications. Understanding how these segments interact enables leaders to design modality-specific service bundles, tailor clinician training, and prioritize investments that support both clinical effectiveness and patient experience.

Regional analysis of how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence adoption, infrastructure investment, and policy-driven ESRD care models

Regional dynamics materially influence care delivery choices, investment priorities, and regulatory approaches to ESRD management. In the Americas, healthcare systems vary from single-payer to mixed models, which affects reimbursement levers, adoption rates of home modalities, and private-sector participation in service delivery. This region often leads in device adoption and telehealth integration but also faces concentrated workforce shortages in rural areas that constrain access. Policy debates and payer initiatives shape capital allocation and incentives for value-based care across national and subnational jurisdictions.

Europe, Middle East & Africa present a heterogeneous mix of regulatory environments and infrastructure capacity that drives divergent adoption patterns. In higher-income European markets, rigorous clinical standards and comprehensive reimbursement frameworks support innovation uptake and robust transplantation programs, while emerging EMEA markets confront infrastructure gaps, limited dialysis capacity, and financing constraints that require scalable, low-resource solutions. Cross-border procurement and regional manufacturing hubs play increasing roles in improving supply reliability and cost efficiency.

Asia-Pacific combines rapidly growing demand, diverse payer structures, and a strong manufacturing base that supports both domestic production and export opportunities. Many health systems in the region are investing in home care models and digital platforms to extend access across urban and peri-urban populations, while also balancing the need to expand transplant infrastructure and workforce training. In each region, stakeholders must tailor strategies to local policy drivers, infrastructure realities, and demographic trends to ensure sustainable service delivery and equitable patient access.

Insightful overview of company strategies that blend product innovation, integrated services, supply chain agility, and regulatory excellence to lead in ESRD care

Competitive and collaborative behaviors among companies active in the ESRD ecosystem are shaping product design, service delivery models, and aftermarket support strategies. Industry participants are increasingly moving from a purely product-centric orientation to integrated service bundles that combine devices, consumables, training, maintenance, and digital monitoring. This shift responds to provider demand for predictable outcomes and to payer interest in measurable, value-based metrics. As a result, firms that can demonstrate robust clinical evidence, comprehensive training programs, and reliable field service capabilities gain a distinct advantage in contracting discussions.

Strategic partnerships, licensing arrangements, and co-development initiatives are becoming more common as companies seek to accelerate time-to-market for incremental innovations while sharing development risk. Contract manufacturing and regional assembly strategies are also expanding to reduce tariff exposure and improve lead times. Firms that invest in interoperable software and open-data approaches position themselves to participate in care networks and population health initiatives. Additionally, aftermarket services-ranging from consumable supply logistics to predictive maintenance and remote troubleshooting-are emerging as meaningful differentiators that influence customer retention and lifetime value.

Finally, companies that prioritize regulatory excellence and health economics evidence generation improve their access to premium procurement pathways and payer negotiations. The most resilient firms pair strong clinical pipelines with scalable service models and agile supply chains to meet the evolving needs of providers and patients in diverse care settings.

Actionable recommendations for leaders to scale home modalities, strengthen supply chains, advance digital integration, and influence policy to secure long-term ESRD performance

Industry leaders must take decisive, coordinated steps to translate evolving evidence and operational pressures into sustainable competitive advantage. First, organizations should prioritize expansion of home-based modalities alongside robust patient education and remote monitoring programs to align with patient preferences and reduce system-level burdens. Such investments should be accompanied by clear clinical pathways and outcome metrics that enable continual improvement. Second, firms and providers must diversify supply chains through nearshoring, multi-sourcing, and validated local partnerships to reduce exposure to tariff fluctuations and logistic disruptions.

Third, stakeholders should pursue interoperable digital platforms that integrate device telemetry, electronic health records, and patient-reported outcomes to support proactive care management and value-based contracting. Fourth, workforce development is critical: invest in scalable training programs that upskill nurses, technicians, and care coordinators to support home therapies and telehealth-enabled workflows. Fifth, engage proactively with policymakers and payers to shape reimbursement frameworks that reward demonstrated improvements in patient-centered outcomes, access, and long-term cost efficiencies. Finally, adopt a portfolio approach to innovation that balances near-term operational improvements with longer-term investments in transplant support, vascular access innovation, and minimally invasive technologies.

By implementing these actions in a coordinated manner, leaders can improve clinical outcomes, protect margins against external shocks, and position their organizations for sustained leadership as care models continue to evolve.

Explanation of a rigorous multi-method research methodology combining primary stakeholder engagement, literature synthesis, case studies, scenario testing, and expert advisory validation

The research underpinning these insights draws on a multi-method approach designed to triangulate clinical evidence, operational practice, and policy developments. Primary sources included structured engagements with clinicians, supply chain managers, health system executives, and payers to capture frontline perspectives on modality adoption, access management, and procurement challenges. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical practice guidelines, and public policy documents to validate clinical efficacy and regulatory trajectories. These inputs informed qualitative synthesis and thematic analysis focused on patient pathways, device life-cycle management, and service model economics.

To ensure robustness, the methodology incorporated targeted case studies of exemplar provider systems and suppliers that have implemented home dialysis scale-ups, integrated remote monitoring, or resilient procurement strategies. Scenario analysis explored plausible supply chain and policy developments to stress-test strategic options, while an advisory panel of clinical and operational experts reviewed findings and recommended refinements. Data integrity measures included cross-validation of procurement and regulatory data points, careful documentation of interview protocols, and iterative reconciliation of stakeholder feedback to minimize bias and ensure relevance across care settings.

This layered approach balances deep qualitative insight with rigorous documentary evidence, producing findings that are actionable for clinicians, administrators, and commercial stakeholders seeking to improve patient outcomes and operational resilience in ESRD care.

Conclusive synthesis emphasizing the interplay of clinical innovation, operational resilience, and collaborative strategies required to improve ESRD care outcomes and access

In synthesis, End Stage Renal Disease care is at an inflection point where clinical innovation, policy incentives, and operational constraints converge to reshape how services are delivered and financed. The growing emphasis on home-based modalities, coupled with advances in vascular access and monitoring technologies, creates tangible opportunities to improve patient experience and outcomes. However, these opportunities coexist with persistent challenges, including workforce shortages, infrastructure gaps, and supply chain vulnerabilities that require deliberate mitigation strategies.

Leaders who proactively realign procurement, clinical pathways, and digital integration will be better positioned to manage external shocks and deliver on value-based objectives. Equally important is the need for collaborative approaches that bring together clinicians, payers, manufacturers, and patient advocates to design pragmatic solutions that scale across diverse settings. By focusing on modular, interoperable solutions, strengthening local manufacturing and supplier networks, and rigorously measuring patient-centered outcomes, stakeholders can enhance access and resilience while preserving clinical excellence.

Ultimately, the pathway forward requires coordinated investment and disciplined execution. Organizations that integrate these insights into strategic plans will not only improve care for patients living with ESRD but also create sustainable operating models that withstand market and policy volatility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of home hemodialysis driven by telehealth integration to improve patient adherence and reduce hospitalization rates
  • 5.2. Emergence of wearable artificial kidneys designed for ambulatory dialysis to enhance patient mobility and quality of life
  • 5.3. Increasing utilization of precision medicine biomarkers to predict residual renal function decline and personalize treatment regimens
  • 5.4. Rising investments in peritoneal dialysis infrastructure to address increasing demand in emerging markets and reduce healthcare costs
  • 5.5. Integration of artificial intelligence algorithms in dialysis machines for real time monitoring and predictive maintenance alerts

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. End Stage Renal Disease Market, by Treatment Modality

  • 8.1. Hemodialysis
    • 8.1.1. Home
    • 8.1.2. Incenter
  • 8.2. Peritoneal Dialysis
    • 8.2.1. Continuous Ambulatory Peritoneal Dialysis
    • 8.2.2. Continuous Cycling Peritoneal Dialysis
  • 8.3. Transplant
    • 8.3.1. Deceased Donor
    • 8.3.2. Living Donor

9. End Stage Renal Disease Market, by Access Type

  • 9.1. Arteriovenous Fistula
  • 9.2. Central Venous Catheter
  • 9.3. Synthetic Graft

10. End Stage Renal Disease Market, by End User

  • 10.1. Dialysis Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. End Stage Renal Disease Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. End Stage Renal Disease Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. End Stage Renal Disease Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Fresenius Medical Care AG & Co. KGaA
    • 14.3.2. DaVita Inc.
    • 14.3.3. Baxter International Inc.
    • 14.3.4. B. Braun Melsungen AG
    • 14.3.5. Nipro Corporation
    • 14.3.6. NxStage Medical, Inc.
    • 14.3.7. U.S. Renal Care, Inc.
    • 14.3.8. Satellite Healthcare, Inc.
    • 14.3.9. Dialysis Clinic, Inc.
    • 14.3.10. Jafron Biomedical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 240. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 241. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 242. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 243. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 244. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 245. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 246. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 247. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 282. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 283. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 284. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 285. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 286. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 287. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 288. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 289. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 296. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 297. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 298. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 299. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 300. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 301. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 302. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 303. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA END STAGE RENAL